TABLE 2.
Association between the risk score model and patients’ clinical characteristics.
| Variables | TCGA cohort (n = 491), n (%) | Risk score |
P-value | |
| Low risk (n = 233) | High risk (n = 258) | |||
| Age (mean ± SD, years) | 61.0 ± 6.8 | 60.3 ± 6.9 | 61.6 ± 6.7 | 0.045 |
| ≤60 years | 221 (45.0) | 115 (49.4) | 106 (41.1) | 0.070 |
| >60 years | 270 (55.0) | 118 (50.6) | 152 (58.9) | |
| Pathological T stage | 0.001 | |||
| T2 | 185 (37.7) | 108 (46.4) | 77 (29.8) | |
| T3 | 290 (59.1) | 120 (51.5) | 170 (65.9) | |
| T4 | 10 (2.0) | 3 (1.3) | 7 (2.7) | |
| Unknown | 6 (1.2) | 2 (0.8) | 4 (1.6) | |
| Nodal stage | <0.001 | |||
| N0 | 341 (69.4) | 173 (74.2) | 168 (65.1) | |
| N1 | 78 (15.9) | 19 (8.2) | 59 (22.9) | |
| Unknown | 72 (14.7) | 41 (17.6) | 31 (12.0) | |
| Gleason score | <0.001 | |||
| 6 | 45 (9.2) | 28 (12.1) | 17 (6.6) | |
| 7 | 245 (49.9) | 150 (64.4) | 95 (36.8) | |
| 8 | 64 (13.0) | 22 (9.4) | 42 (16.3) | |
| 9 | 134 (27.3) | 33 (14.1) | 101 (39.1) | |
| 10 | 3 (0.6) | 0 (0) | 3 (1.2) | |
| PSA at initial diagnosis (ng/ml) | 0.011 | |||
| ≤4 | 58 (11.8) | 22 (9.4) | 36 (14.0) | |
| (4,10] | 268 (54.6) | 144 (61.8) | 124 (48.1) | |
| (10,20) | 98 (19.9) | 45 (19.3) | 53 (20.5) | |
| >20 | 53 (10.8) | 16 (6.9) | 37 (14.3) | |
| Unknown | 14 (2.9) | 6 (2.6) | 8 (3.1) | |